As a pharmaceutical company headquartered in Zurich, Switzerland, we develop, manufacture and internationally market well-proven and innovative pharmaceuticals in novel drug delivery forms.
Established in 1836, today Acino has a global footprint with the clear focus on over 90 high-growth markets. Our company has evolved significantly in the past decades, and we happily celebrate our cultural and geographic diversity.
As a leader in advanced drug delivery technologies with a focus on modified release and dispersible forms, for which we also hold patents, we are renowned for the quality of products, people, and service.
Group sales
for full-year 2023
Sales % in high-growth markets
in 2023
Employees
as of end of 2023
Manufacturing sites:
Switzerland (2), Ukraine,
Estonia, United Arab Emirates
and South Africa
Regional offices:
Dubai, Kyiv, Johannesburg,
and Mexico City
We believe in entering partnerships for the expansion of our product portfolio, the acquisition of unique drug delivery technologies, and for specific dossiers that meet our commercial plans. We provide contract manufacturing services, offer products through distribution deals, as well as through out- and in-licensing. We strive for long-lasting relationships with suppliers, distributors, and customers.
We use cookies to create statistics that help us to improve the quality of our website and your user experience. By clicking on “Accept All”, you consent to the processing of data by Acino and the transfer of data to third parties. You can also tailor your consent for specific data processing purposes. Once you have made your choice, click on “Confirm”. Find detailed information and modify your preferences at any time in our Privacy Notice.
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
We would like to set Google Analytics cookies to help us analyse the traffic on our website.